Follow
Francesco Cucco
Francesco Cucco
Department of Pathology, University of Cambridge
Verified email at cam.ac.uk
Title
Cited by
Cited by
Year
Mutation Spectrum and Genotype–Phenotype Correlation in C ornelia de L ange Syndrome
L Mannini, F Cucco, V Quarantotti, ID Krantz, A Musio
Human mutation 34 (12), 1589-1596, 2013
1942013
Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial
A Davies, TE Cummin, S Barrans, T Maishman, C Mamot, U Novak, ...
The Lancet Oncology 20 (5), 649-662, 2019
1722019
Molecular high-grade B-cell lymphoma: defining a poor-risk group that requires different approaches to therapy
C Sha, S Barrans, F Cucco, MA Bentley, MA Care, T Cummin, H Kennedy, ...
Journal of Clinical Oncology 37 (3), 202, 2019
1422019
Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit
F Cucco, S Barrans, C Sha, A Clipson, S Crouch, R Dobson, Z Chen, ...
Leukemia 34 (5), 1329-1341, 2020
402020
Genome stability: What we have learned from cohesinopathies
F Cucco, A Musio
American Journal of Medical Genetics Part C: Seminars in Medical Genetics …, 2016
382016
Mutant cohesin affects RNA polymerase II regulation in Cornelia de Lange syndrome
L Mannini, F C Lamaze, F Cucco, C Amato, V Quarantotti, IM Rizzo, ...
Scientific reports 5 (1), 1-11, 2015
372015
Mutant cohesin drives chromosomal instability in early colorectal adenomas
F Cucco, A Servadio, V Gatti, P Bianchi, L Mannini, A Prodosmo, ...
Human molecular genetics 23 (25), 6773-6778, 2014
332014
SMC1B is present in mammalian somatic cells and interacts with mitotic cohesin proteins
L Mannini, F Cucco, V Quarantotti, C Amato, M Tinti, L Tana, A Frattini, ...
Scientific reports 5 (1), 1-11, 2015
312015
Pathogenic variants in EP300 and ANKRD11 in patients with phenotypes overlapping Cornelia de Lange syndrome
F Cucco, P Sarogni, S Rossato, M Alpa, A Patimo, A Latorre, C Magnani, ...
American Journal of Medical Genetics Part A 182 (7), 1690-1696, 2020
252020
CEP57 mutation in a girl with mosaic variegated aneuploidy syndrome
L Pinson, L Mannini, M Willems, F Cucco, N Sirvent, T Frebourg, ...
American Journal of Medical Genetics Part A 164 (1), 177-181, 2014
232014
Sequential inverse dysregulation of the RNA helicases DDX3X and DDX3Y facilitates MYC-driven lymphomagenesis
C Gong, JA Krupka, J Gao, NF Grigoropoulos, G Giotopoulos, R Asby, ...
Molecular Cell 81 (19), 4059-4075. e11, 2021
192021
Separase prevents genomic instability by controlling replication fork speed
F Cucco, E Palumbo, S Camerini, B D’Alessio, V Quarantotti, ML Casella, ...
Nucleic acids research 46 (1), 267-278, 2018
192018
Thyroid MALT lymphoma: Self-harm to gain potential T-cell help
F Wu, N Watanabe, MM Tzioni, A Akarca, C Zhang, Y Li, Z Chen, F Cucco, ...
Leukemia 35 (12), 3497-3508, 2021
102021
Mutation screening using formalin-fixed paraffin-embedded tissues: a stratified approach according to DNA quality
F Cucco, A Clipson, H Kennedy, J Sneath Thompson, M Wang, S Barrans, ...
Laboratory Investigation 98 (8), 1084-1092, 2018
102018
Transmission of diffuse large B-cell lymphoma by an allogeneic stem-cell transplant
S Araf, J Wang, M Ashton-Key, K Korfi, D Di Bella, A Rio-Machin, ...
haematologica 104 (4), e174, 2019
52019
Genetic Characterization and Clinical Features of Helicobacter pylori Negative Gastric Mucosa-Associated Lymphoid Tissue Lymphoma
B Kiesewetter, C Copie-Bergman, M Levy, F Wu, J Dupuis, C Barau, ...
Cancers 13 (12), 2993, 2021
42021
Widespread in situ follicular neoplasia in patients who subsequently developed follicular lymphoma
R Dobson, A Wotherspoon, SA Liu, F Cucco, Z Chen, Y Tang, MQ Du
The Journal of Pathology 256 (4), 369-377, 2022
12022
Gene expression profiling in an open-label randomised phase 3 trial (REMoDL-B) of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma
A Davies, T Cummin, S Barrans, T Maishman, C Mamot, U Novak, ...
The Lancet Oncology 20 (5), 649-662, 2019
12019
9p gain predicts outcomes in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated with R-GemOx+/-Atezolizumab. ARGO: a randomised phase II study
A Davies, P McKay, W Osborne, L Stanton, O Tansley‐Hancock, ...
Hematological Oncology 39 (S2), 155-156, 2021
2021
MOLECULAR HIGH GRADE (MHG) GENE EXPRESSION PROFILE IN DLBCL IS ENRICHED AMONG PATIENTS WITH EARLY TREATMENT FAILURE
SL Barrans, F Cucco, J Davies, M van Hoppe, T Mell, K Mercer, l Stanton, ...
Hematological Oncology 39, 2021
2021
The system can't perform the operation now. Try again later.
Articles 1–20